A modified international prognostic index including pretreatment hemoglobin level for early stage extranodal natural killer/T cell lymphoma

Leukemia & Lymphoma
Liang WangYu-jing Zhang

Abstract

In this study, we investigated the prognostic role of pretreatment hemoglobin level in 321 patients with stage I/II extranodal natural killer (NK/T cell lymphoma (ENKTL). Patients with pretreatment hemoglobin level < 120 g/L had significantly inferior progression-free survival (PFS) and overall survival (OS) than those with hemoglobin level ≥ 120 g/L (p < 0.05). In a multivariate Cox regression model, age, Eastern Cooperative Oncology Group (performance status), lactate dehydrogenase level, Ann Arbor stage and pretreatment hemoglobin level were all independent prognostic factors for PFS and OS (p < 0.05). Using these five parameters, a modified international prognostic index (mIPI) model was constructed. This mIPI could categorize three groups with significantly different PFS and OS (both p < 0.0001) in both the training set and the validation set. In conclusion, this study confirmed the prognostic role of pretreatment hemoglobin level in ENKTL, and a newly modified IPI including pretreatment hemoglobin level could be used to further optimize treatments for patients with stage I/II ENKTL, especially in the era of asparaginase.

References

Jun 14, 1990·The New England Journal of Medicine·C B MillerJ L Spivak
Mar 15, 1983·Cancer·N DainiakR Hoffman
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Jan 1, 1997·Advances in Experimental Medicine and Biology·S M EvansC J Koch
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M M CheungR K Ngan
Dec 3, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I MoulletB Coiffier
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G E KimB S Kim
Feb 9, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·D M BrizelM W Dewhirst
Jul 13, 2000·The Oncologist·P Kumar
Jul 15, 2000·The Oncologist·P Kumar
Sep 7, 2000·International Journal of Radiation Oncology, Biology, Physics·M HenkeR Guttenberger
Aug 17, 2002·International Journal of Radiation Oncology, Biology, Physics·Michael M C CheungWilliam W L Foo
May 6, 2004·Blood·Philippe Solal-CélignyEmili Montserrat
Sep 30, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Heinz LudwigDirk Schrijvers
Dec 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeeyun LeeWon Seog Kim
Aug 25, 2007·International Journal of Radiation Oncology, Biology, Physics·Tomasz RutkowskiAdam Idasiak
Mar 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ye-Xiong LiZi-Hao Yu
Apr 8, 2011·International Journal of Radiation Oncology, Biology, Physics·Ye-Xiong LiZi-Hao Yu
Oct 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Motoko YamaguchiRitsuro Suzuki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.